Novartis Estradiol Patch
Princeton, New Jersey, December 22, 2014 – Sandoz today announced the US market introduction of estradiol transdermal system, an authorized generic version of Vivelle-Dot®, which is marketed by Novartis Pharmaceuticals Corporation. Estradiol transdermal system is indicated for treatment of certain menopausal symptoms and for the prevention of postmenopausal osteoporosis.
“We are pleased to partner with our colleagues at NPC to further expand our offering of affordable, high-quality medicines,” said Peter Goldschmidt, President of Sandoz Inc. According to IMS Health, US sales for estradiol transdermal system were USD 263 million for the 12 months ending in September 2014. Sandoz will market the product in.025mg / day,.0375mg / day,.05mg / day,.075mg / day, and.1mg / day, of estradiol, the same strengths marketed by Novartis Pharmaceuticals Corporation. IMPORTANT SAFETY INFORMATION Estrogen-Alone Therapy Endometrial Cancer There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Adding a progestin to estrogen therapy has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer.
Adequate diagnostic measures, including directed or random endometrial sampling when indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding. Cardiovascular Disorders and Probable Dementia Estrogen-alone therapy should not be used for the prevention of cardiovascular disease or dementia. The Women's Health Initiative (WHI) estrogen-alone substudy reported increased risks of stroke and deep vein thrombosis (DVT) in postmenopausal women (50 to 79 years of age) during 7.1 years of treatment with daily oral conjugated estrogens (CE) [0.625mg]-alone, relative to placebo.
278 rows Up to TI-83/84 Plus BASIC Math. So download this program just. Origionally used for just the distance formula, every. Download distance formula ti 84 program.